NCT02337205View on ClinicalTrials.gov

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Actinic Keratosis
Interventions
DRUG

KX2-391 Ointment

KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.

Trial Locations (1)

78759

DermResearch, Inc., Austin

Sponsors

Lead Sponsor

Athenex, Inc.
All Listed Sponsors
lead

Athenex, Inc.

INDUSTRY